Last reviewed · How we verify
Intravenous Tirofiban
Tirofiban is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors.
Tirofiban is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors. Used for Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction), Percutaneous coronary intervention.
At a glance
| Generic name | Intravenous Tirofiban |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Glycoprotein IIb/IIIa inhibitor |
| Target | Glycoprotein IIb/IIIa receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Tirofiban reversibly inhibits the glycoprotein IIb/IIIa receptor on platelet surfaces, which is the final common pathway for platelet aggregation. By blocking this receptor, tirofiban prevents platelets from clumping together and forming thrombi, reducing the risk of acute ischemic events in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.
Approved indications
- Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)
- Percutaneous coronary intervention
Common side effects
- Bleeding
- Thrombocytopenia
- Hypotension
- Bradycardia
Key clinical trials
- Tirofiban After Successful MT Recanalization in AIS (PHASE2, PHASE3)
- Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (PHASE3)
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion (PHASE3)
- Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke
- Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke (NA)
- Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Tirofiban CI brief — competitive landscape report
- Intravenous Tirofiban updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI